Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.

Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E.

Br J Cancer. 2016 Jan 19;114(2):177-87. doi: 10.1038/bjc.2015.398. Epub 2015 Dec 22.

2.

Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.

Némati F, Daniel C, Arvelo F, Legrier ME, Froget B, Livartowski A, Assayag F, Bourgeois Y, Poupon MF, Decaudin D.

Anticancer Drugs. 2010 Jan;21(1):25-32. doi: 10.1097/CAD.0b013e3283300a29.

PMID:
19823076
3.

Hormone escape is associated with genomic instability in a human prostate cancer model.

Legrier ME, Guyader C, Céraline J, Dutrillaux B, Oudard S, Poupon MF, Auger N.

Int J Cancer. 2009 Mar 1;124(5):1103-11. doi: 10.1002/ijc.24073.

4.

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.

Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Pérez-Soler R, Horwitz SB, McDaid HM.

Cancer Res. 2007 Dec 1;67(23):11300-8.

5.

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.

Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boyé K, de Cremoux P, Dutrillaux B, Poupon MF.

Br J Cancer. 2007 Jan 29;96(2):269-76. Epub 2007 Jan 9.

6.

Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.

Auger N, Thillet J, Wanherdrick K, Idbaih A, Legrier ME, Dutrillaux B, Sanson M, Poupon MF.

Mol Cancer Ther. 2006 Sep;5(9):2182-92.

7.

Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft.

Legrier ME, de Pinieux G, Boyé K, Arvelo F, Judde JG, Fontaine JJ, Bara J, Poupon MF.

Br J Cancer. 2004 Feb 9;90(3):720-7.

8.

Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.

Oudard S, Legrier ME, Boyé K, Bras-Gonçalves R, De Pinieux G, De Cremoux P, Poupon MF.

J Urol. 2003 May;169(5):1729-34.

PMID:
12686819
9.

[A new model of human prostate cancer, the PAC120 xenograft].

Legrier ME, de Pinieux G, Poirson-Bichat F, Apiou F, Dutrillaux AM, Boye K, Sihassen A, Lidereau R, Bara J, Arvelo F, Dutrillaux B, Poupon MF.

Pathol Biol (Paris). 2003 Feb;51(1):1-4. Review. French.

PMID:
12628285
10.

Cell cycle regulation during mouse olfactory neurogenesis.

Legrier ME, Ducray A, Propper A, Chao M, Kastner A.

Cell Growth Differ. 2001 Dec;12(12):591-601.

11.

Region-specific expression of cell cycle inhibitors in the adult brain.

Legrier ME, Ducray A, Propper A, Kastner A.

Neuroreport. 2001 Oct 8;12(14):3127-31.

PMID:
11568650
12.

Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach.

de Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Gonçalves R, Dutrillaux AM, Némati F, Oudard S, Lidereau R, Broqua P, Junien JL, Dutrillaux B, Poupon MF.

Am J Pathol. 2001 Aug;159(2):753-64.

Supplemental Content

Loading ...
Support Center